FdCyd

Peroxymonosulfate (PMS) activation is a promising technology for water purification, but the removal performance of multiple pollutant matrices and the mechanism for reactive species transformation in the heterogeneous catalytic system remain ambiguous. Herein, a novel CuFe₂O₄/diatomite was fabricated for PMS activation to achieve efficient removal of typical pesticides. Uniform distribution of CuFe₂O₄ on diatomite efficiently alleviated the agglomeration of CuFe₂O₄ and increased specific surface area (57.20 m² g^-1, 3.8-fold larger than CuFe₂O₄). CuFe₂O₄/5% diatomite (5-CFD)/PMS system showed nearly 100% removal efficiency for mixed pesticide solution within 10 min (0.10 g L^-1 5-CFD and 0.40 g L^-1 PMS) and excellent anti-interference performance towards various coexisting substances (≥90% removal efficiency). The electrochemical measurements confirmed that the lower charge transfer resistance of 5-CFD significantly enhanced the electron-transfer capacity between 5-CFD and PMS, accelerating the reactions among Fe(III)/Fe(II), Cu(II)/Cu(I), and PMS, further generating •OH (261.3 μM), ¹O₂ (138.8 μM), SO₄^•- (11.8 μM), and O₂^•-. The O in reactive oxygen species didn't originate from dissolved oxygen (DO) but PMS, independent of the low solubility of DO and slow diffusion rate of O₂ in water. Furthermore, the production of ¹O₂ went through the process: PMS → O₂^•- → ¹O₂, and SO₄^•- could rapidly convert into •OH. The degradation pathways and the evolution of intermediates were proposed by HPLC-QTOF-MS/MS and DFT calculations. QSAR analysis illustrated that the toxicity became lower with the reaction process. This study provides novel insights into the mechanism for pesticide degradation and active species transformation and the anti-interference capability of systems.

Lymphatic drug delivery (LDD) is an attractive option for the prevention and treatment of cancer metastasis. This study aims to develop TPGS decorated nanostructure lipid carrier gefitinib loaded (TPGS-NLC-GEF). Biocompatibility and cytotoxicity were studied using erythrocytes and A549 cell lines. Furthermore, cellular uptake of the prepared TPGS-NLC was studied using 5-carboxyfluorescein (5-CF). Pharmacokinetic, biodistribution, and chylomicron-block flow studies were performed using male Wister Albino rats to investigate the influence of TPGS-NLC on plasma concentration-time profile, organ deposition, and LDD of GEF. The present results indicated that the prepared TPGS-NLC and TPGS-NLC-GEF formulation had a particle size range of 268 and 288 nm with a negative zeta-potential value of - 29.3 and - 26.5 mV, respectively. The in-vitro release showed burst drug release followed by sustained release. In addition, the biosafety in the term of the hemocompatibility study showed that the prepared formulation was safe at the therapeutic level. Additionally, an in-vitro cytotoxicity study showed that the TPGS-NLC was able to enhance the activity of GEF against the A549 cell line. The cellular uptake study showed the ability of TPGS-NLC to enhance 5-CF internalization by 12.6-fold compared to the 5-CF solution. Furthermore, the in-vivo study showed that TPGS-NLC was able to enhance GEF bioavailability (1.5-fold) through lymphatic system which was confirmed via the indirect chylomicron-block flow method. The tissue distribution study showed the ability of lipid nanoparticles to enhance lung drug deposition by 5.8-fold compared to a GEF suspension. This study concluded that GEF-NLC-GEF is an encouraging approach for the treatment of metastatic lung cancer through lymphatic delivery, enhanced bioavailability, and reduced systemic toxicity.